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Running title: Familial second cancers and NHL 
 
Novelty and Impact: Familial risks of nine particular cancers were associated with risks of second 
primary cancers (SPCs), and, in addition, any family history was associated with the risk. The 
results showed that in NHL patients with an SPC, SPC was the most common cause of death and 
accounted for 40% of deaths. Consistently, SPCs negatively influenced survival rates. Survival in 
non-Hodgkin lymphoma was worsened by second primary cancer, particularly, if it was known to 
be fatal as first primary cancer. 
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Second primary cancers (SPCs) account for an increasing proportion of all cancer diagnoses and 
family history of cancer may be a risk factor for SPCs. Using the Swedish Family-Cancer 
Database on non-Hodgkin lymphoma (NHL), we assessed the influence of family history on risk 
of SPCs and of SPCs on survival. NHL patients were identified from the years 1958 to 2015 and 
generalized Poisson models were used to calculate relative risks (RRs) for SPCs and familial 
SPCs. Among 14,393 NHL patients, a total of 1,866 (13.0%) were diagnosed with SPC. Familial 
risk of nine particular cancers were associated with risks of these cancers as SPCs, with 2 to 5-
fold increases in RRs. At the end of a 25-year follow-up period, the survival probability for 
persons with SPC was only 20% of that for patients without SPC; the hazard ratio for SPC was 
1.59 (95% CI: 1.46 – 1.72). Survival could be predicted by the prognostic groups based on first 
cancers and HRs increase systematically with worse prognosis yielding a trend of P = 4.6x10-5. 
SPCs had deleterious consequences for survival in NHL patients. Family history was associated 
with increasing numbers of SPCs. Prevention of SPCs and their early detection is an important 
target in the overall strategy to improve survival in NHL patients. Counseling for avoidance of 







Non-Hodgkin lymphoma (NHL) is the most common hematological malignancy, for which risk 
factors include immunosuppression and other types of immunodeficiency and autoimmunity, chronic 
inflammation induced by viral or other microbial causes and family history of NHL 1, 2. Survival of 
NHL depends on tumor subtypes, the most common of which include a relatively benign follicular 
lymphoma and aggressive diffuse large B-cell lymphoma 3. The management of NHL has evolved 
over the years and this has contributed to the improved survival rate 1, 4-6. In particular, with the 
advent of rituximab around 2002, survival has improved dramatically for many subtypes of NHL 7-9. 
Consequently, an increasing number of second primary cancers (SPCs) are being observed in NHL 
survivors 10-16. According to our recent study, around 1 in 12 NHL patients are diagnosed with an 
SPC 17.  
 
In the present study, we focused on familial risk factors and consequences of SPC in terms of 
mortality. We report on 14,393 NHL patients, based on an analysis from the Swedish Family-Cancer 
Database. Our goal was to examine two novel aspects of SPCs in NHL patients. We hypothesize that 
family history of a particular cancer may increase the risk of that cancer to appear as SPC; thus, a 
family history of breast cancer may increase the frequency of breast cancer as SPC in NHL patients. 
There is previous evidence on increased risk of SPC associated with family history in survivors of 
Hodgkin lymphoma and multiple myeloma 18, 19. We further hypothesized that mortality of patients 
with SPC may be influenced by the type of SPC, which is in-line with distinct mortality differences 
known for first primary cancers 20, 21. While family history may increase the numbers of SPCs we 
wanted, in addition, to test whether it also interferes with survival in NHL patients. 
 
PATIENTS AND METHODS 
 
The Swedish Family-Cancer Database includes data on the Swedish population collated in family 
data and is linked to the Swedish Cancer Registry, which was founded in 1958 and covers the entire 
population with more than two million cancers included in the dataset 22. The registry is based on 
compulsory cancer notifications made by clinicians and pathologists/cytologists 23. Since the mid-
1980’s, there are six regional registries associated with the oncological centers in each medical 
region of Sweden where the registration, coding and major check-up and correction work is 
performed. The regionalization implies a high level of quality as a result of close contact between the 
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Swedish Cancer Registry at the regional level and the reporting clinician thus simplifying the task of 
checking and correcting the data. All registered NHL cases were histologically verified. While the 
cancer registry does not publish separate statistics on histological verification of SPCs, they are 
included with primary cancers for which histological verification has been approximately 98% from 
the 1970s onwards 24. An ad hoc study on the diagnostic accuracy of second neoplasms found 98% 
to be correctly classified 25. NHLs were identified through reference to the 7th revision of 
International Classification of Diseases (ICD). NHL patients were followed from diagnosis until 
death, detection of an SPC, emigration or December 31, 2015, whichever came first. NHL patients 
with second primary NHL were not considered. Person-years and SPCs were categorized according 
to age (5-year bands), sex, socioeconomic index (six groups), region (four groups) and calendar year. 
Category-specific incidence rates among NHL patients were multiplied by the corresponding person-
years at risk to estimate the expected number of malignancies in respective strata.  
 
Relative risks (RRs) were assessed for SPC by means of incidence rate ratios, regressed over a fixed-
effects generalized Poisson model. RRs for SPCs were obtained by comparing incidence rates for 
each SPC in NHL patients with respective population background rates for primary cancer. In 
familial analyses, RRs were calculated for the offspring generation (born after 1931). Family history 
was recorded from the beginning of cancer registration in Sweden (1958 onwards). The family 
history was called when the SPC was the same, concordant cancer, which was diagnosed in the first-
degree relative (parent or sibling). Sex, age group, calendar-period, socioeconomic status and 
residential areas were treated as potential confounders and were adjusted for in the multivariable 
regression model. We used waiting time distribution with Poisson assumption to estimate RRs and 
corresponding confidence intervals (CIs) were calculated for 5%, 1% and 0.1% levels of significance 
respectively, and p-values associated with RRs were obtained with two-tailed tests against Chi-
square distribution with one degree of freedom 26. Test of trend was performed to compare RRs of 
familial cases of SPCs to that of non-familial cases obtained from the Poisson regression. 
  
Survival was modeled with multivariable Cox-regression model, meeting the proportional-hazards 
assumption, adjusted for sex, age group, residential area and socioeconomic status. In this model, the 
diagnosis of SPC was treated time-dependent variable in order to avoid the immortal time bias 27. 
Deaths due to NHL or any other cause resulted in censoring.  Considering the large changes in 
incidence and survival in NHL, we restricted survival analysis to the latter part of the total follow-up, 
starting follow-up from 1991 and thus rendering 25 years of maximal follow-up time. We assessed 
survival probabilities and hazard ratios (HRs) of NHL patients with SPC against the baseline hazard 
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for patients without SPC. We grouped SPCs into three ‘prognostic groups’ based on 5-year relative 
survival of these cancers as first primary cancer 28, 29: ‘good survival’ (relative survival >60%) 
included cancers in lip, larynx, anus, breast, cervix, endometrium, prostate, testis, male genitals, 
kidney, bladder, melanoma, skin (squamous cell, SCC), eye, thyroid gland and endocrine and 
Hodgkin lymphoma; ‘moderate survival’ (40-60%) included cancers in upper aerodigestive tract 
(except lip and larynx), salivary glands, small intestine, colorectum, female genitals, bone and 
connective tissue and non-Hodgkin lymphoma; ‘poor survival’ (<40%) included cancers in stomach, 
esophagus, liver, pancreas, lung, ovary and nervous system and myeloma. We analyzed the effect of 
family history of cancer on survival with further stratification. To obtain a deeper understanding of 
this impact of specific family histories, we also analyzed cancer type specific survival.  
 
Causes of death were available in the database as obtained from the national causes of death register. 
The underlying cause of death is ascertained by merging the cancer registry and the death certificate 
notification 30. Causes of deaths were annotated with the following ICD codes, ICD-7 (1958 –1968), 
ICD-8 (1969 – 1986), ICD-9 (1987 - 1996) and with ICD-10 (1997 onwards). All cancer-related 
deaths were stratified into NHL, SPC, ‘higher order primaries’, ‘other cancer’ and non-neoplastic 
cause of death ‘other causes’. ‘Other cancer’ includes cases diagnosed at the issue of death 
certificates, referred to ‘death certificate notifications’ 23, 30, 31. These notifications are not used by the 
Swedish Cancer Registry to complement cancer data in contrast to the other Nordic Cancer 
Registries 23, 30, 31. We have found that the notifications often included multiple cancers and cancer of 
unknown primary (CUP). In our previous studies, we have earlier used these notifications as 
information on metastases 32, 33. If the death certificate notification matched the organ site of the 
reported primary cancer it was classified to that site but in some cases, when such an assignment 
could not be made, the classification was put to ‘other cancer’. A small number (N=63) of NHL 
patients were reported to have NHL as SPC; these were not considered.   
 
All statistical analyses were done with R version 3.5 and SAS version 9.4. 
 
The study was approved by the Ethical Committee of Lund University, without requirement for 
informed consent. People could choose to opt out before the research database was constructed, 
which was advertised in major newspapers. The project database is located at the Center for Primary 






A total of 14,393 NHL patients (median age at diagnosis 59 years) belonged to the offspring 
generation for which RRs were calculated. A total of 1,866 (13.0%) of these patients were diagnosed 
with SPC; of these 1,250 (67.0%) had a first-degree family history of any cancer (median follow-up 
to SPC six years) while 616 had no family history but the median follow-up to SPC was also six 
years. The total number of deaths numbered 5,271 (36.6% of all NHL patients), of which 4,267 had 
no SPC (34.1% of all NHL patients without SPC) while 1,004 had an SPC (53.8% of all with SPC).   
 
Familial risks for SPC are shown in Table 1 for 12 cancers with two or more concordant familial 
patients (i.e. SPC was the same cancer that was diagnosed in the family member) and, in the bottom 
line, for any familial patients, including concordant and discordant family histories. The risk for SPC 
without family history was increased for many SPCs but we used trend test to assess the influence of 
family history on risk. For nine cancers the trend test was significant. The test was highly significant 
for breast (RR, 2.55 [95% CI, 1.79 – 3.63] with family history against an RR of 0.92 [0.75 – 1.13] 
without family history) and prostate cancers (1.88 [1.49 – 2.37] vs. 0.84 [0.74 – 0.97]). The 
differences between these RRs were much higher for stomach cancer (10.92 [4.90 – 24.33] vs. 2.26 
[1.61 – 3.19]), bladder cancer (4.56 [2.17 – 9.56] vs. 1.90 [1.52 – 2.38]), melanoma (4.03 [1.81 – 
8.98] vs. 1.66 [1.33 – 2.06]) and cancer of unknown primary (CUP, 7.02 [2.92 – 16.87] vs. 2.08 
[1.59 – 2.73]). For NHL with SPSs of ‘any’, concordant and discordant family history, the RRs were 
1.86 [1.76 – 1.96] vs. 1.58 [1.46 – 1.71].    
 
We analyzed familial risks separately in two periods 1958-2003 and 2004-2015 in order to test if 
new therapies, such as rituximab, might have influenced familial risk 7. For family history of any 
concordant SPC the case numbers were too few (51 in the latter and 141 in the former period) to 
provide conclusive results. We analyzed also family histories after specific histological subtypes of 
NHL (which were available from 1993 onwards). For diffuse large B-cell lymphoma, 31 SPCs with a 
concordant family history were recorded; for follicular lymphoma the number was 40. As the family 
histories covered approximately 10 different cancers the small case numbers did not allow 
conclusions about the possible histological differences.      
 
Follow-up for survival studies started from 1991 and covered 11,586 NHL patients in the offspring 
generation of whom 3,661 (31.6%) had died by the end of 2015. SPC had deleterious consequences 
for survival in NHL (Fig. 1). Kaplan-Meier survival curves started to diverge from year six onwards, 
and by the end of 25-year follow-up in 2015, the survival probability for persons with SPC was only 
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20% of patients without SPC. The HR for patients with SPC was 1.59 (1355 cases, 688 deaths, 95% 
CI 1.46-1.72) compared to the baseline hazard (HR 1.00) of those without SPC (10,231 cases, 2973 
deaths). Survival in NHL patients with SPC and family history was marginally worse (HR 1.07 [0.91 
– 1.25]) than in those with SPC lacking a family history. We explored also the influence of some of 
the most common family histories and a concordant family history of breast cancer was particularly 
unfavorable (HR 2.64 [1.13  – 9.01] among 17 cases and 9 deaths) while concordant family histories 
of colorectal and prostate cancers did not influence survival (data not shown). 
 
For the NHL patients with SPC, causes of death are shown in Table 2. As of the end of 2015, a total 
of 1,004 (53.8%) patients had died. SPCs accounted for 40.0% of all causes of death, followed by 
non-neoplastic ‘other causes’ (23.8%) and first primary cancer (20.9%), i.e. NHL. Fatal SPCs 
included esophageal, liver, lung and stomach cancers for which 70% or more of patients died of 
SPC. ‘Other causes’ were the most common cause of death for endocrine, skin (SCC) and a few 
other SPC patients. ‘Other neoplasia’ accounted for more than half of deaths for CUP.  
 
Survival analysis among patients with SPC and stratified in prognostic groups (see methods) is 
shown in Fig. 2. We observed monotonically differentiated survival probabilities in-line with the 
prognostic stratification: cancers with good prognosis (HR of 1.05 [1.00 – 1.12] among 759 cases 
and 276 deaths), moderate prognosis (1.42 [1.14 – 1.79] among 349 cases and 204 deaths) and poor 
prognosis (2.27 [1.73 – 2.82] among 210 cases and 171 deaths). A trend test over the three 





The four novel findings of the present study on SPCs after NHL included demonstration of an 
increased risk of SPCs depending on family history. Furthermore, there was unfavorable overall 
survival in patients with SPC and high mortality related to defined SPCs. In addition, as a related 
finding, there was unfavorable survival depending on the prognostic group of SPCs. We showed that 
for nine concordant cancers, family history was associated with a significant risk of SPCs including 
cancers such as breast, prostate and bladder cancers and melanoma for with the RRs were increased 
from 2 to 5-fold. Even for any family history (concordant and discordant) the RR was highly 
significant, 1.86 vs. 1.58 compared to those without family history. Previous evidence along the 
same lines was reported for rarer cancers, Hodgkin lymphoma and multiple myeloma 18, 19. Family 
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history and testing for genetic susceptibility offers a strategy for prevention of fatal SPC when taken 
at NHL diagnosis, and relevant advice could be given, for example, regarding lung cancer (smoking 
cessation), colorectal, prostate and skin cancers (screening) and stomach and bladder cancer (early 
signs).    
 
We tested also whether family history of SPC might have changed after introduction of novel 
therapies around 2003 or whether family histories of SPCs were distinct for histological types of 
NHL. However case numbers in both of these analyses were too few to allow conclusions. We have 
addressed the same questions in our recent study on SPCs in NHL irrespective of family history 17. 
Even among all SPCs, no definite changes could be found in the period-specific analysis 
(Supplementary Tables 4 and 5 17). However histological types of NHL showed distinct patterns of 
SPCs which appeared to correlate with survival rates for the specific subtypes 17.   
 
As for the second novel part, the dramatically worse survival in patients with SPC shown in Kaplan-
Meier survival analysis where the curve for patients with SPC departed from NHL without SPC at 
six years of follow-up and reached by 25 years to only 20% of the survival probability for patients 
without SPCs. Although family history contributed to increased numbers of SPCs, as pointed out 
above, it did not influence overall survival. However, the HR for survival in patients with breast 
cancer with a concordant family history was unfavorable (2.64 [1.13 – 9.01]). However, case 
numbers were small. 
 
According to the third novelty, we showed that mortality of SPCs was in line with known mortality 
of first primary cancers. Both the most fatal (esophageal, liver, lung and stomach) and least fatal 
(endocrine, skin) cancers were among those predicted from survival studies among first cancers 20, 21. 
Unexpectedly, for CUP as SPC other neoplasia was given as the cause of death in over half of the 
patients. The reason for this is the Swedish practice of assigning death in CUP patients to the fatal 
metastatic cancer that the death registrar assumed to be the final cause 34; CUP is the most fatal of all 
cancers with a median survival of two months and indeed we observed a mortality rate of 98% (57 of 
58 NHL patients with CUP as SPC had died) 35.  
 
As the related (fourth) novelty, we formally tested survival in three prognostic groups, which were 
constructed from the reported survival experience of first primary cancers 28, 29. Survival could be 
predicted by the prognostic groups and HRs increase systematically from no SPC 1.00 to good 
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prognosis 1.05, moderate prognosis 1.42 and poor prognosis 2.27. A trend test over the three 
prognostic groups was convincing, P = 4.6x10-5. 
 
The strengths of this study include extensive nationwide coverage of cancers, high level of 
histological verification of the reported cancers and, for the family study, practically complete 
national family structures 22, 30. Critical to the present study is the level of reporting of SPCs, which 
in Sweden is mandated by the overall obligation to report all cancers and certain other tumors to the 
cancer registry; consequently, some 20% of the reported cancers are multiple primaries 24. The high 
level of reporting of SPC is also evident in international pooling studies where the Swedish rates of 
SPCs are among the highest of all cancer registries 10. Limitations of the study are small case 
numbers when considering familial risk and SPC, rare events for any particular cancer, even in the 
present largest study published on the subject. We were lacking clinical data at presentation, any 
treatment data and some possible risk factors which may confound the observed associations. In the 
future, with accumulating case numbers, it will be possible to test the findings in the largest subtypes 
of NHL.   
 
In conclusion, our results showed that SPCs have deleterious consequences for survival in NHL 
patients. The consequences were particularly devastating for cancers classified as fatal primary 
cancers. Family history augmented the deleterious consequences by contributing increasing numbers 
of SPCs. Hence prevention of SPC by considering individual risk factors (such as smoking) and by 
careful monitoring of family history would be important targets in the overall strategy to improve 
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Fig 1. Kaplan-Meier survival curves for non-Hodgkin lymphoma patients with and without second 
primary cancer since 1991 (SPC). The shading around the curves shows 95%CIs.   
 
 
Fig 2. Kaplan-Meier survival curves for non-Hodgkin lymphoma patients (1991 onwards) with 
second primary cancer divided in three prognostic groups based on survival of these cancers as first 
primary cancers, as described in methods : ‘good prognosis’. relative survival >60%, ‘moderate 
prognosis’, relative survival 40-60%, and ‘poor prognosis’, relative survival <40%. The shading 







Table 1 Relative risks of second primary cancers among non-Hodgkin lymphoma survivors stratified 
over family history of cancer  
 
Abbreviations: 
FDR, first degree relative; N, total number; RR, relative risk; LCI, UCI, lower and upper 95% confidence intervals; 
*Cancer sites with at least two or more familial cases are shown; ‘All’ includes all cancer sites. 
**Bold, italics and underline represent 5%, 1% and 0.01% level of significance. 
 
 With family history No family history Trend test     P value 
Second primary 
cancer N RR LCI UCI N RR LCI UCI 
Upper aerodigestive 
tract 2	 4.10	 1.03	 16.40	 45	 2.21	 1.65	 2.96	 0.092	
Stomach 6	 10.92	 4.90	 24.33	 33	 2.26	 1.61	 3.19	 0.013	
Colorectum Colorectum 24	 2.09	 1.40	 3.12	 131	 1.35	 1.14	 1.60	 0.002	
Lung 19	 3.44	 2.19	 5.40	 127	 1.64	 1.38	 1.95	 0.008	
Breast 31	 2.55	 1.79	 3.63	 96	 0.92	 0.75	 1.13	 <0.001	
Prostate 71	 1.88	 1.49	 2.37	 205	 0.84	 0.74	 0.97	 <0.001	
Kidney 2	 3.25	 0.81	 12.99	 58	 2.59	 2.00	 3.36	 0.269	
Urinary bladder 7	 4.56	 2.17	 9.56	 76	 1.90	 1.52	 2.38	 0.017	
Melanoma 6	 4.03	 1.81	 8.98	 79	 1.66	 1.33	 2.06	 0.019	
Skin (squamous cell 
carcinoma) 13	 7.43	 4.31	 12.80	 216	 5.11	 4.46	 5.85	 0.009	
Leukemia 4	 4.85	 1.82	 12.92	 121	 4.55	 3.80	 5.45	 0.215	
Cancer of unknown 
primary 5	 7.02	 2.92	 16.87	 53	 2.08	 1.59	 2.73	 0.037	
Any 1250	 1.86	 1.76	 1.96	 616	 1.58	 1.46	 1.71	 <0.001	
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Table 2 Distribution of causes of death in non-Hodgkin lymphoma patients with second primary 




N, Total number; %, percentage; 
  
 











Second primary cancer N % N % N % N % N % Upper aerodigestive tract 8 24.2 7 21.2 3 9.1 1 3.0 14 42.4 Esophagus 13 86.7 2 13.3 - - - - - - Stomach 21 70.0 2 6.7 - - 6 20.0 1 3.3 Colorectum 40 49.4 10 12.3 1 1.2 5 6.2 25 30.9 Liver 23 74.2 3 9.7 - - 2 6.5 3 9.7 Pancreas 23 65.7 3 8.6 - - 3 8.6 6 17.1 Lung 88 72.7 12 9.9 1 0.8 4 3.3 16 13.2 Breast 10 28.6 10 28.6 6 17.1 2 5.7 7 20.0 Endometrium 3 33.3 2 22.2 2 22.2 - - 2 22.2 Ovary 6 60.0 - - 1 10.0 1 10.0 2 20.0 Prostate 18 20.5 26 29.5 5 5.7 7 8.0 32 36.4 Kidney 11 36.7 5 16.7 3 10.0 3 10.0 8 26.7 Urinary	bladder 12 29.3 12 29.3 3 7.3 - - 14 34.1 Melanoma 9 36.0 5 20.0 3 12.0 1 4.0 7 28.0 Skin	(squamous cell carcinoma) 2 2.1 31 32.3 7 7.3 18 18.8 38 39.6 Nervous	system 12 40.0 9 30.0 1 3.3 2 6.7 6 20.0 Endocrine	glands - - 3 27.3 - - 1 9.1 7 63.6 Hodgkin	lymphoma 7 41.2 5 29.4 2 11.8 - - 3 17.6 Multiple	myeloma 9 60.0 2 13.3 - - 1 6.7 3 20.0 Leukemia 45 45.0 33 33.0 3 3.0 4 4.0 15 15.0 
Cancer of unknown primary	 8 14.0 10 17.5 - - 33 57.9 6 10.5 Total	 377 40.0 197 20.9 42 4.5 101 10.7 224 23.8 
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